140 related articles for article (PubMed ID: 27530021)
1. [REACTIVATION OF TUBERCULOSIS PRESENTING WITH EMPYEMA DUE TO ANTICANCER CHEMOTHERAPY FOR DIFFUSE LARGE B CELL LYMPHOMA].
Yuba T; Hatsuse M; Kodama M; Uda S; Yoshimura A; Kurisu N
Kekkaku; 2016 Apr; 91(4):475-9. PubMed ID: 27530021
[TBL] [Abstract][Full Text] [Related]
2. [Development tuberculous meningitis during chemotherapy for CD5-positive diffuse large B-cell lymphoma].
Teramura Y; Kameda K; Kanda J; Gomyo A; Hayakawa J; Akahoshi Y; Komiya Y; Harada N; Ugai T; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Wada H; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Kako S; Kanda Y
Rinsho Ketsueki; 2016 May; 57(5):597-601. PubMed ID: 27263784
[TBL] [Abstract][Full Text] [Related]
3. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
5. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
6. Primary diffuse large B-Cell lymphoma of the prostate presenting with urinary retention and dyschezia for which rituximab-combined CHOP therapy was effective-a case presentation.
Manabe M; Hayashi Y; Yoshii Y; Mukai S; Sakamoto E; Kanashima H; Nakao T; Hayama T; Fukushima H; Inoue T; Yamane T; Teshima H
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1733-5. PubMed ID: 23152030
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP.
Ribera JM; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M; Navarro JT; Feliu E
Br J Haematol; 2012 Jun; 157(5):637-9. PubMed ID: 22313456
[No Abstract] [Full Text] [Related]
8. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
9. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
[TBL] [Abstract][Full Text] [Related]
10. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.
Mian M; Augustin F; Kocher F; Gunsilius E; Willenbacher W; Zabernigg A; Zangerl G; Oexle H; Schreieck S; Schnallinger M; Fiegl M
Anticancer Res; 2014 May; 34(5):2559-64. PubMed ID: 24778077
[TBL] [Abstract][Full Text] [Related]
11. Lymphomatous pericardial effusion positive for Mycobacterium tuberculosis by PCR analysis.
Michelis FV; Petrogiannopoulos CL; Papamichael KX; Kostakos ND; Kiagia EZ; Deliousis A; Zacharof AK
Int J Infect Dis; 2008 Sep; 12(5):564-5. PubMed ID: 18406651
[No Abstract] [Full Text] [Related]
12. [A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma].
Nakashima T; Kiba T; Ogawa Y; Kimura A; Kido M; Okikawa Y; Ito T; Saito A; Hosokawa A; Shintani H; Okada Y; Taniguchi T; Taniyama K; Kozawa K; Niimi H
Gan To Kagaku Ryoho; 2012 May; 39(5):809-12. PubMed ID: 22584337
[TBL] [Abstract][Full Text] [Related]
13. A case of duodenal malignant lymphoma presenting as acute pancreatitis: systemic lupus erythematosus and immunosuppressive therapy as risk factors.
Yamada R; Sakuno T; Inoue H; Miura H; Takeuchi T; Shiono Y; Okuse H; Nakamura M; Katsurahara M; Hamada Y; Tanaka K; Horiki N; Takei Y
Clin J Gastroenterol; 2018 Aug; 11(4):286-290. PubMed ID: 29546569
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
[TBL] [Abstract][Full Text] [Related]
15. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
17. Comparison of therapeutic outcomes between surgical resection followed by R-CHOP and R-CHOP alone for localized primary intestinal diffuse large B-cell lymphoma.
Lee HS; Park LC; Lee EM; Shin SH; Ye BJ; Oh SY; Song MK; Lee SM; Lee WS; Kang BW; Chang MH; Cho SG; Yahng SA; Yoon SS; Kwon JH; Kim YS
Am J Clin Oncol; 2014 Apr; 37(2):182-7. PubMed ID: 23211226
[TBL] [Abstract][Full Text] [Related]
18. R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma.
Fowler NH
Clin Adv Hematol Oncol; 2014 Sep; 12(9):608-10. PubMed ID: 25654483
[No Abstract] [Full Text] [Related]
19. Posterior reversible encephalopathy syndrome (PRES) complicating newly-diagnosed diffuse large B-cell lymphoma.
Sengupta S; Benkers T; Blitstein M; Palmer E; Plotkin SR; Abramson JS
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):e111-3. PubMed ID: 24581553
[No Abstract] [Full Text] [Related]
20. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]